Why we need a new way to judge the value of medicine
We need to shift the conversation to focus on value and outcomes delivered, rather than on isolated costs of therapies, writes the CEO of Novartis.
1982, Bachelor's degree, Stanford; 1984, MBA, UC Berkeley. Formerly: Head, North America and Head, EU Business, Heinz. With Novartis: 2007, Head, Consumer Health; Head, Novartis Pharma, moving portfolio towards newly launched products. Since 2010, Chief Executive Officer, Novartis. Former Non-Executive Director, AZ. Adviser, Private Equity, US Blackstone Group. Member of the Board, General
Motors.
We need to shift the conversation to focus on value and outcomes delivered, rather than on isolated costs of therapies, writes the CEO of Novartis.
Joseph Jimenez looks at the scientific and research revolution going on in China.
We’ve only just begun to see the potential of medical advances in areas of innovation like genomics.